Detay

French SME working with hematological cancers, especially to Multiple Myeloma offers a wide range of services to test new therapeutic drugs

BOFR20151013003

A French company offers to pharmaceutical and biotechnology companies a wide range of services to test new therapeutic drugs in Multiple Myeloma cell models and in other haematological cancers (platform of service dedicated to identification, assessment of drug efficiency, characterization of mechanism of action, Identification of the most effective combinations with conventional treatments or with other molecules to cover MM heterogeneity). They are looking for partners for services agreement.

Close link to hospital laboratory and its dedicated research team in the field of haematological cancers. Company founders have developed: 1. A unique collection of 40 human MM cell lines, perfectly characterized 2. Constitution of a collection of human Lymphoma cell lines 3. Signatures to predict drug response patented (innovative biomathematical approach. 4. Capacity to analyze and integrate biological or medical datasets into logical and reliable « data informations » 5. Strong collaborations with R&D laboratory and interactions with clinical trials in haematological malignancies 6. Original and expert services proposed

The offeror is an expert company devoted to haematological cancers, especially to Multiple Myeloma (MM). This French company offers to pharmaceutical and biotechnology companies an in vitro assessment of drug efficiency, characterization of mechanism of action, identification of the most effective combinations with conventional treatments or with other molecules to cover MM heterogeneity and identification of predictive biomarkers of drug response. The strength of the company lies in its close link to hospital laboratory and its dedicated research team in the field of haematological cancers. The company offers to pharmaceutical and biotechnology companies a wide range of services to test new therapeutic drugs in MM cell models and in other haematological cancers (platform of service dedicated to identification, assessment of drug efficiency): • Define the IC50 in large collection of Human Multiple Myeloma cell lines and/or in other haematological cancer cell lines. Cell Cycle analysis and characterization of cell death. Signalling pathways. • Understanding the mechanisms of action of the molecule • Identification of the most effective combinations with conventional treatments or with other molecules. • Characterization of the effect in “resistant-myeloma cell lines” • Characterization of the effect of the molecule on normal plasma cells differentiation (on the different steps of plasma cell maturation). The company is looking for partners for services agreement. Companies, R&D Institution or University that want to screen therapeutic agents, to identify hits and leads and to assess of drug efficiency. They are also looking for identifying potential partners for drug out licensing/co-development in the domain of haematological malignancies.

2.11.2016

20.10.2015

3.11.2015

Keyword

06001003Drilling, completion and stimulation
06001005Storage and transportation
06002002Nuclear
06002007In vitro Testing, Trials
06003001Solar/thermal energy

04009In vitro Testing, Trials
04014Bioinformatics
05001001Diagnostic services
05001005Molecular diagnosis
05005014Oncology

M.71.2.0Technical testing and analysis
M.72.1.1Research and experimental development on biotechnology

İş Birliği

Secret Know-how,Exclusive Rights)

1. Pharmaceutical, biotechnological companies that want to screen therapeutic agents, to identify hits and leads and to assess of drug efficiency (Understanding the mechanisms of action of the molecule, identification of the most effective combinations with conventional treatments or with other molecules, characterization of the effect in “resistant myeloma cell lines”) 2. Identify potential partners for drug out licensing/co-development (small to big-size companies) in the domain of haematological malignancies.

SME 11-50,University,R&D Institution,>500 MNE,251-500,SME 51-250,>500

Already on the market

Alan

Bio Chem Tech

Müşteri

Industry SME <= 10

English French

France

<1M

Hayır

Services agreement